Search

Learn about the different types of benign breast lumps.

… Friday, May 24, 2024 What should you do if you notice a lump in your breast? Don’t panic. See your doctor. “Many lumps turn out to be benign,” says Memorial Sloan Kettering Cancer Center breast radiologist Kimberly N. Feigin, MD , Acting Chief of Breast Radiology at MSK. “But the most important thing

New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease.

… Tuesday, May 20, 2014 Data Supports Routine Tumor Genotyping for Patients with Advanced Lung Cancers; May Improve Survival New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for

Immunotherapy pioneers Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSK), and Carl June, MD, of the University of Pennsylvania, have published a seminal review of the current landscape of chimeric antigen receptor (CAR) therapy in the New England Journal of Medicine (NEJM). In the comprehensive review article, Drs. Sadelain and June highlight the emerging immunotherapy treatment for hematologic cancers known as CAR T cells, which was developed at MSK. The paper is the first in a series being published by NEJM. Known as Frontiers in Medicine, it will showcase ways that new technologies are influencing contemporary medicine and science.

… Wednesday, July 4, 2018 Immunotherapy pioneers Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSK), and Carl June, MD, of the University of Pennsylvania, have published a seminal review of the current landscape of chimeric antigen receptor (CAR) therapy in the New England Journal

Researchers at MSK published updated data today in the New England Journal of Medicine from the ongoing, single-arm Phase II VISION study evaluating tepotinib as a single agent in patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations.

… Friday, May 29, 2020 Researchers at Memorial Sloan Kettering Cancer Center (MSK) published updated data today in the New England Journal of Medicine from the ongoing, single-arm phase II VISION study evaluating tepotinib as a single agent in patients with advanced non-small cell lung cancer (NSCLC) with

Longtime donors Fiona and Stanley Druckenmiller have contributed a transformative gift of $100 million to MSK through their foundation. The gift will be used to launch the Fiona and Stanley Druckenmiller Presidential Innovation Fund.

… Tuesday, January 11, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of the Fiona and Stanley Druckenmiller Presidential Innovation Fund. The new initiative, made possible by a transformative $100 million gift from the Fiona and Stanley Druckenmiller Foundation, is expected

Deb Schrag, MD, MPH, gastrointestinal oncologist and Chair of the Department of Medicine, presented results from a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total surgical excision for the treatment of patients with locally advanced rectal cancer.

… Sunday, June 4, 2023 New data led by researchers at Memorial Sloan Kettering Cancer Center (MSK) and Dana-Farber Brigham Cancer Center featured in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting press program and simultaneously published in  The New England Journal of Medicine (NEJM

… Thursday, April 3, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Almudena Chaves Perez, Adriana Mujal, Hina Shah, and Lydia Paraskevi Tsamouri Awarded the 2025 Kravis WiSE Fellowships Almudena Chaves Perez, Adriana Mujal, Hina Shah, and Lydia

… Tuesday, December 2, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Omar Abdel-Wahab Elected to the National Academy of Medicine (NAM) Omar Abdel-Wahab Omar Abdel-Wahab, MD , Chair of the Molecular Pharmacology Program at Sloan Kettering Institute

Justin Perry, PhD, cell biologist and immunologist of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named a recipient of the 2021 National Institutes of Health (NIH) Director’s New Innovator Award.

… Tuesday, October 5, 2021 Justin Perry, PhD , cell biologist and immunologist of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 64 recipients of the prestigious 2021 National Institutes of Health (NIH) Director’s New Innovator Award . As part of the award, Dr. Perry

Learn how multiple myeloma prognosis has improved significantly with the emergence of new drug treatments.

… Tuesday, January 27, 2026 Note: This story was originally published in 2022 and has been updated. Saad Usmani, MD , a hematologic oncologist specializing in multiple myeloma , is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center (MSK). Dr. Usmani has more than 15 years of experience